FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014848092> ?p ?o ?g. }

• W2014848092 endingPage "8" @default.
• W2014848092 startingPage "63" @default.
• W2014848092 abstract "Complex perioperative immunodysfunction occurs in patients with renal cell carcinoma undergoing nephrectomy. Here, the effect of pretreatment with IL-2 is addressed. Of 63 patients who underwent tumour nephrectomy, 26 patients received four doses of 10 Mio IE/m2 IL-2 b.d. s.c. (i.e. a total of 40 Mio IE/m2) a week before operation, 37 did not. Parameters of cellular and humoral immunity (differential blood count, T-cell markers CD2, CD3, CD4, and CD8, B-cell markers CD19 and CD20, monocyte markers CD13 and CD14, NK-cell marker CD16, activation markers CD25, CD26, CD69 and HLA-DR, and cytokines IL-1-receptor antagonist (IL-1RA), IL-2, soluble IL-2-receptor (sIL-2R), IL-6, IL-10, and TGFbeta) were measured in peripheral venous blood. Blood was drawn before IL-2, one day before and immediately after the operation, and on the 1st, 3rd, 5th, and 10th postoperative day. All patients showed postoperatively elevated leukocyte and granulocyte counts, and elevated serum levels of cytokines IL-6 and IL-10. T-cell and activation markers were decreased. However, all these alterations were less accentuated in patients who had been pretreated with IL-2. Monocyte counts and IL-2 and TGFbeta levels were decreased, but IL-1RA and sIL-2R levels were elevated in pretreated patients. IL-2-related toxicity was WHO grade I-II in all patients, grade III in one patient. The anaesthetic regimen had no measurable effect. IL-6 concentrations were higher in renal venous than in venous pool blood, indicating IL-6 production in the tumour in vivo. Tumour-specific survival was better in pretreated patients with tumours extending beyond the kidney. Pretreatment with IL-2 modulates perioperative immunodysfunction in patients undergoing tumour nephrectomy. This affects in particular T-cell-mediated immunity and levels of cytokines IL-10 and IL-6. The IL-2 application scheme used here was followed by distinct counter regulation including monocytes, IL-2, sIL-2R, IL-1RA and TGFbeta. Taken together, pretreatment with IL-2 may complement surgery in the treatment of patients with renal cell carcinoma, and may help close the therapeutic gap between neo-adjuvant and adjuvant immunotherapy." @default.
• W2014848092 created "2016-06-24" @default.
• W2014848092 creator A5027184477 @default.
• W2014848092 creator A5029167913 @default.
• W2014848092 creator A5043835936 @default.
• W2014848092 creator A5045536574 @default.
• W2014848092 date "2003-01-01" @default.
• W2014848092 modified "2023-09-26" @default.
• W2014848092 title "Pretreatment with interleukin-2 modulates perioperative immunodysfunction in patients with renal cell carcinoma." @default.
• W2014848092 cites W140710454 @default.
• W2014848092 cites W1484067190 @default.
• W2014848092 cites W1964398262 @default.
• W2014848092 cites W1970066014 @default.
• W2014848092 cites W1972229497 @default.
• W2014848092 cites W1977559040 @default.
• W2014848092 cites W1985482500 @default.
• W2014848092 cites W1986395580 @default.
• W2014848092 cites W1987306080 @default.
• W2014848092 cites W1990113106 @default.
• W2014848092 cites W1991335135 @default.
• W2014848092 cites W1996367219 @default.
• W2014848092 cites W1996997726 @default.
• W2014848092 cites W2009771778 @default.
• W2014848092 cites W2017236844 @default.
• W2014848092 cites W2017576359 @default.
• W2014848092 cites W2019050518 @default.
• W2014848092 cites W2026073203 @default.
• W2014848092 cites W2028269517 @default.
• W2014848092 cites W2055818786 @default.
• W2014848092 cites W2058554371 @default.
• W2014848092 cites W2069392891 @default.
• W2014848092 cites W2071635471 @default.
• W2014848092 cites W2072209115 @default.
• W2014848092 cites W2075222049 @default.
• W2014848092 cites W2080704532 @default.
• W2014848092 cites W2082045877 @default.
• W2014848092 cites W2083368878 @default.
• W2014848092 cites W2084333330 @default.
• W2014848092 cites W2085196145 @default.
• W2014848092 cites W2093224997 @default.
• W2014848092 cites W2096900830 @default.
• W2014848092 cites W2107625369 @default.
• W2014848092 cites W2112113822 @default.
• W2014848092 cites W2137493116 @default.
• W2014848092 cites W2139557613 @default.
• W2014848092 cites W2145676488 @default.
• W2014848092 cites W2151754709 @default.
• W2014848092 cites W2171344915 @default.
• W2014848092 cites W2171499071 @default.
• W2014848092 cites W2172266254 @default.
• W2014848092 cites W2264124631 @default.
• W2014848092 cites W2412719933 @default.
• W2014848092 cites W2415050988 @default.
• W2014848092 cites W2416146067 @default.
• W2014848092 cites W2419506590 @default.
• W2014848092 cites W2423395848 @default.
• W2014848092 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12779014" @default.
• W2014848092 hasPublicationYear "2003" @default.
• W2014848092 type Work @default.
• W2014848092 sameAs 2014848092 @default.
• W2014848092 citedByCount "9" @default.
• W2014848092 countsByYear W20148480922015 @default.
• W2014848092 countsByYear W20148480922017 @default.
• W2014848092 countsByYear W20148480922018 @default.
• W2014848092 crossrefType "journal-article" @default.
• W2014848092 hasAuthorship W2014848092A5027184477 @default.
• W2014848092 hasAuthorship W2014848092A5029167913 @default.
• W2014848092 hasAuthorship W2014848092A5043835936 @default.
• W2014848092 hasAuthorship W2014848092A5045536574 @default.
• W2014848092 hasConcept C126322002 @default.
• W2014848092 hasConcept C134018914 @default.
• W2014848092 hasConcept C147483822 @default.
• W2014848092 hasConcept C167672396 @default.
• W2014848092 hasConcept C170493617 @default.
• W2014848092 hasConcept C203014093 @default.
• W2014848092 hasConcept C2776090121 @default.
• W2014848092 hasConcept C2777371288 @default.
• W2014848092 hasConcept C2777472916 @default.
• W2014848092 hasConcept C2778690821 @default.
• W2014848092 hasConcept C2780091579 @default.
• W2014848092 hasConcept C2780227381 @default.
• W2014848092 hasConcept C3017875465 @default.
• W2014848092 hasConcept C43044207 @default.
• W2014848092 hasConcept C71924100 @default.
• W2014848092 hasConcept C74172505 @default.
• W2014848092 hasConcept C79484868 @default.
• W2014848092 hasConcept C8891405 @default.
• W2014848092 hasConcept C90924648 @default.
• W2014848092 hasConceptScore W2014848092C126322002 @default.
• W2014848092 hasConceptScore W2014848092C134018914 @default.
• W2014848092 hasConceptScore W2014848092C147483822 @default.
• W2014848092 hasConceptScore W2014848092C167672396 @default.
• W2014848092 hasConceptScore W2014848092C170493617 @default.
• W2014848092 hasConceptScore W2014848092C203014093 @default.
• W2014848092 hasConceptScore W2014848092C2776090121 @default.
• W2014848092 hasConceptScore W2014848092C2777371288 @default.
• W2014848092 hasConceptScore W2014848092C2777472916 @default.
• W2014848092 hasConceptScore W2014848092C2778690821 @default.

• next